Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor
NCT02544451
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
246
Enrollment
INDUSTRY
Sponsor class
Conditions
Cystic Fibrosis
Interventions
DRUG:
LUM/IVA
DRUG:
LUM/IVA
Sponsor
Vertex Pharmaceuticals Incorporated